Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2010

View Archived Issues

PHY-906 beneficial when added to capecitabine in phase II pancreatic cancer trial

Perifosine plus capecitabine active in mCRC; phase III study planned

Enrollment begins into clinical trial of Alinia for acute uncomplicated influenza

PharmAthene submits White Paper for development of SparVax anthrax vaccine

Kyowa Hakko Kirin and Hisamitsu sign distribution agreement in Japan for KW-2246

Abbott and Pierre Fabre sign exclusive worldwide licensing agreement for h224G11

MK-0646 added to gemcitabine and erlotinib active in advanced pancreatic cancer

GI-4000 plus gemcitabine evaluated in ras mutation-bearing pancreas cancer

Mitaplatin targets both mitochondria and nucleus selectively in cancer cells

YM BioSciences merges with Cytopia

NeuroMed describes novel T-type voltage-gated calcium channel blockers

Novel antimicrobial agents discovered by French scientists

Kalbitor now available on U.S. market

Anadys discovers NS5B inhibitors for treatment of HCV infections

Novel NURR1/NOT ligands described by sanofi-aventis

Ariad claims new activin receptor-like kinase inhibitors for cancer therapy

FDA accepts Topica's luliconazole IND to begin trials in onychomycosis

Pearl raises funds to advance PT-003 combination bronchodilator for COPD

Pervasis receives FDA clearance for pivotal phase III Vascugel trial

Mepact for osteosarcoma reaches first market

Edoxaban enters phase III thromboembolism trial

FDA reports safety risk associated with HIV drug Videx

Cephalon enters agreement to acquire Mepha

Neuralstem treats first patient in ALS stem cell trial

Novartis reports fourth quarter and full year 2009 results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.